Federated Hermes Inc. grew its position in Cardlytics, Inc. (NASDAQ:CDLX – Get Rating) by 14,385.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,991 shares of the company’s stock after buying an additional 133,066 shares during the period. Federated Hermes Inc. owned 0.40% of Cardlytics worth $1,260,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in CDLX. Rhumbline Advisers boosted its position in shares of Cardlytics by 2.6% during the 1st quarter. Rhumbline Advisers now owns 34,150 shares of the company’s stock worth $1,878,000 after purchasing an additional 856 shares during the period. FMR LLC raised its holdings in shares of Cardlytics by 238.4% in the 2nd quarter. FMR LLC now owns 1,428 shares of the company’s stock valued at $32,000 after purchasing an additional 1,006 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Cardlytics by 7.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,580 shares of the company’s stock valued at $392,000 after purchasing an additional 1,184 shares in the last quarter. Amundi raised its holdings in shares of Cardlytics by 65.8% in the 2nd quarter. Amundi now owns 3,504 shares of the company’s stock valued at $48,000 after purchasing an additional 1,390 shares in the last quarter. Finally, Hsbc Holdings PLC raised its holdings in shares of Cardlytics by 41.2% in the 1st quarter. Hsbc Holdings PLC now owns 5,149 shares of the company’s stock valued at $287,000 after purchasing an additional 1,503 shares in the last quarter. Hedge funds and other institutional investors own 88.22% of the company’s stock.
Analysts Set New Price Targets
CDLX has been the topic of a number of analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Cardlytics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Thursday, March 2nd. Needham & Company LLC reduced their price objective on shares of Cardlytics from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, March 2nd. Finally, Wells Fargo & Company cut their price target on shares of Cardlytics from $6.00 to $5.00 and set an “underweight” rating on the stock in a research note on Thursday, March 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Cardlytics presently has an average rating of “Hold” and a consensus target price of $8.00.
Cardlytics Stock Down 9.9 %
Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.
- Get a free copy of the StockNews.com research report on Cardlytics (CDLX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.